Filing Flows › Alphatec Holdings (ATEC) › Recalls, complaints & regulation
Alphatec Holdings (ATEC): recalls and clinical trials
Alphatec Holdings (ATEC) beyond its filings: 3 recalls in the last 12 months (7 in five years, 0 Class I); 2 active clinical trials.
Latest recalls
- 2026-07-29 · FDA device · SafeOp Patient Interface, REF: AIX11240, part of SafeOp 3: Neural Informatix System
- 2026-02-18 · FDA device · ATEC Lateral Navigation Disc Prep Instruments LIF NAV, OSTEOTOME 10mm REF 267-01-000-10-N UDI-DI code: 00190376541471; GMDN 12844 The ATEC Navigation Disc
- 2026-02-18 · FDA device · ATEC Lateral Navigation Disc Prep Instruments LIF NAV, OSTEOTOME 10mm REF 266-01-000-10-N UDI-DI code: 00190376476179; GMDN 12844 The ATEC Navigation Disc
- 2025-02-05 · FDA device · Calibrate CCX Interbody System for spinal fusion procedures: Implants: (1) Calibrate CCX-O, 7 x 10 x 25mm 5 degrees, Part #325-07102505, nonsterile;
- 2024-03-06 · FDA device · IdentiTi ALIF Standalone Interbody System: Part Number/Description 132-10-85-250 / IdentiTi ALIF SA Graft Bolt, 08.5 x 25 mm 132-10-85-300 / IdentiTi ALIF SA
- 2023-09-06 · FDA device · LIF AMP, Adjustable Awl, REF 117-165, Part of the AMP System. Used with Spine Lateral Interbody Systems, IdentiTi LIF, Transcend LIF and Battalion LLIF,
- 2022-11-16 · FDA device · Disc Preparation instruments contained in the following products: CI-11050-08102515 Longer IdentiTi PO Trial Tip, 11A X 8P X 10 X 25mm, 15¿ TC11050 00840180
Alphatec Holdings' latest quarter
Alphatec Holdings, Q3 2026: revenue $221M (+13% year over year), operating margin 1.5%, net loss $5.5M, operating cash flow $18.9M. The chart follows the revenue to costs, profit and cash.
Questions
Has Alphatec Holdings had any recalls?
7 recalls on file over five years from the FDA, CPSC and NHTSA; 3 in the last 12 months.
How many clinical trials does Alphatec Holdings have?
2 active studies on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.